Business
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH® in the EU and that no additional Phase 3 studies are required – – Verrica is initiating activities to support this regulatory submission, which could be filed as early as Q4 2026 – WEST CHESTER, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”)
About this update from Verrica Pharmaceuticals Inc.
[{"type":"image","alt":"Verrica Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Verrica Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":268,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/35B6rwmMy25cs4KMlGMlxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b","width":268,"height":117}},"lazy":false},{"type":"text","content":"– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH® in the EU and that no additional Phase 3 studies are required –","length":271,"tagName":"p"},{"type":"text","content":"– Verrica is initiating activities to support this regulatory submission, which could be filed as early as Q4 2026 –","length":116,"tagName":"p"},{"type":"text","content":"WEST CHESTER, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided positive feedback that supports the filing of a Marketing Authorization Application (MAA) for Verrica’s product, YCANTH®, as a treatment for molluscum contagiosum (“molluscum”).","length":556,"tagName":"p"},{"type":"text","content":"“We are pleased to gain alignment with CHMP with respect to the safety and efficacy data requirements to support an MAA filing for YCANTH in the European Union,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “Based on convincing efficacy data from the well-controlled Phase 3 studies successfully conducted in both the U.S. and Japan, the CHMP concluded that no further Phase 3 clinical studies are needed in order to progress toward a filing for approval. The European market for molluscum represents a significant unmet need for millions of potential patients, and this feedback provides Verrica with a key catalyst to explore a broad range of strategic opportunities for rea...